FDA Approves New Antiviral for InfluenzaAschenbrenner, Diane S., MS, RNAJN The American Journal of Nursing: February 2019 - Volume 119 - Issue 2 - p 21 doi: 10.1097/01.NAJ.0000553202.36589.e2 Drug Watch Buy Abstract Author InformationAuthors Article MetricsMetrics Baloxavir marboxil (Xofluza) is a newly approved antiviral drug to treat influenza. It works by decreasing influenza virus replication. In clinical trials, baloxavir marboxil significantly decreased the duration of flu symptoms compared with placebo. The drug is administered as a single oral dose. It should be given no more than 48 hours after the onset of flu symptoms. Baloxavir marboxil should not be taken with dairy products, calcium-fortified beverages, laxatives, antacids, or oral supplements (such as iron, zinc, selenium, calcium, or magnesium), as these will decrease the circulating dose of the drug. Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: firstname.lastname@example.org. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.